Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/978-94-017-9211-0_16 http://scihub22266oqcxt.onion/10.1007/978-94-017-9211-0_16 C4472007!4472007 !25201201     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25201201 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Subcell+Biochem 2014 ; 85 (ä): 281-319 Nephropedia Template TP {{tp|p=25201201 |t=2014. Targeting p53-MDM2-MDMX loop for cancer therapy |pdf=|usr=}}{{25201201 }} gab.com Text Targeting p53-MDM2-MDMX loop for cancer therapy JO: Subcell Biochem http://www.kidney.de/pget.php?&tw=1&pmid=25201201 #FOAvip The tumor suppressor p53 plays a central role in anti-tumorigenesis and cancer therapy. It has been described as "the guardian of the genome", because it is essential for conserving genomic stability by preventing mutation, and its mutation and inactivation are highly related to all human cancers. Two important p53 regulators, MDM2 and MDMX, inactivate p53 by directly inhibiting its transcriptional activity and mediating its ubiquitination in a feedback fashion, as their genes are also the transcriptional targets of p53. On account of the importance of the p53-MDM2-MDMX loop in the initiation and development of wild type p53-containing tumors, intensive studies over the past decade have been aiming to identify small molecules or peptides that could specifically target individual protein molecules of this pathway for developing better anti-cancer therapeutics. In this chapter, we review the approaches for screening and discovering efficient and selective MDM2 inhibitors with emphasis on the most advanced synthetic small molecules that interfere with the p53-MDM2 interaction and are currently on Phase I clinical trials. Other therapeutically useful strategies targeting this loop, which potentially improve the prospects of cancer therapy and prevention, will also be discussed briefly. Twit Text FOAVip Targeting p53-MDM2-MDMX loop for cancer therapy ????Subcell Biochem http://www.kidney.de/pget.php?&tw=1&pmid=25201201 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25201201 #FOAvip English Wikipedia <ref>{{Cite pmid|25201201 }}</ref> Targeting p53-MDM2-MDMX loop for cancer therapy #MMPMID25201201 Zhang Q ; Zeng SX ; Lu H Subcell Biochem 2014[]; 85 (ä): 281-319 PMID25201201 show ga The tumor suppressor p53 plays a central role in anti-tumorigenesis and cancer therapy. It has been described as "the guardian of the genome", because it is essential for conserving genomic stability by preventing mutation, and its mutation and inactivation are highly related to all human cancers. Two important p53 regulators, MDM2 and MDMX, inactivate p53 by directly inhibiting its transcriptional activity and mediating its ubiquitination in a feedback fashion, as their genes are also the transcriptional targets of p53. On account of the importance of the p53-MDM2-MDMX loop in the initiation and development of wild type p53-containing tumors, intensive studies over the past decade have been aiming to identify small molecules or peptides that could specifically target individual protein molecules of this pathway for developing better anti-cancer therapeutics. In this chapter, we review the approaches for screening and discovering efficient and selective MDM2 inhibitors with emphasis on the most advanced synthetic small molecules that interfere with the p53-MDM2 interaction and are currently on Phase I clinical trials. Other therapeutically useful strategies targeting this loop, which potentially improve the prospects of cancer therapy and prevention, will also be discussed briefly. |*Genes, p53 [MESH] |Antineoplastic Agents/pharmacology/therapeutic use [MESH] |Cell Cycle Proteins [MESH] |Humans [MESH] |Neoplasms/*drug therapy/genetics [MESH] |Nuclear Proteins/*antagonists & inhibitors/genetics/physiology [MESH] |Proto-Oncogene Proteins c-mdm2/*antagonists & inhibitors/genetics/physiology [MESH]Targeting p53-MDM2-MDMX loop for cancer therapy (epmc).pdf DeepDyve Pubget Overpricing